Pharmafile Logo
Pharmafocus logo
Advanced Search

Janssen

Showing 15 posts of 275 posts found.

janssen_latest_logo_on_sign_closer

Janssen’s Stelara shows promise across two dosages in ulcerative colitis

October 9, 2018
Manufacturing and Production, Research and Development Janssen, Stelara, pharma, ulcerative colitis

Janssen’s biologic therapy Stelara (ustekinumab) has shown new efficacy in the treatment of moderate to severe ulcerative colitis in two …

News
msd

MSD signs $117m deal with Samsung Bioepis over Janssen biosimilar

October 8, 2018
Sales and Marketing Biogen, Janssen, MSD, Samsung, Samsung Bioepis

American multinational MSD have won a $117 million contract allowing them to supply Samsung Bioepis’ Renflexis to the US Department …

News
nhs_sign

NHS England to fund availability of Janssen’s single tablet HIV combo Symtuza

October 1, 2018
Sales and Marketing HIV, Janssen, NHS, Symtuza, pharma

Great news for HIV patients in the UK as Janssen reveals that NHS England will provide critical funding for its …

News
janssen_latest_logo_on_sign

Phase 3 data presents strong case for switching from Humira to Janssen’s Tremfya in plaque psoriasis

September 13, 2018
Research and Development Humira, Janssen, Tremfya, pharma, psoriasis

Janssen has unveiled new Phase 3 data derived from two separate trials on the efficacy and benefits of switching to …

News
janssen_latest_logo_on_sign

Europe approves Janssen’s Darzalex in frontline multiple myeloma

September 4, 2018
Manufacturing and Production, Research and Development, Sales and Marketing EU, Europe, J&J, JJ, Janssen, darzalex, multiple myeloma, pharma

Janssen has revealed that its CD38-targeting biologic drug Darzalex (daratumumab) has received approval from the European Commission, authorising its use …

News

Janssen and ViiV’s monthly injectable HIV combo proves non-inferior to daily standard of care

August 15, 2018
Research and Development HIV, Janssen, ViiV Healthcare, pharma

Janssen and GSK’s ViiV Healthcare have unveiled strong new Phase 3 data on its two-drug regimen, injected once a month, …

News
janssen_latest_logo_on_sign

Janssen’s Symtuza scores approval with the FDA in HIV-1

July 18, 2018
Sales and Marketing HIV, Janssen, Symtuza, pharma

Janssen has announced that Symtuza (D/C/F/TAF) has received approval from the FDA in the treatment of human immunodeficiency virus type …

News
jj_sign_on_wall

J&J stops Invokana trial early after success in kidney disease and type 2 diabetes

July 17, 2018
Manufacturing and Production, Research and Development J&J, JJ, Janssen, Johnson & Johnson, invokana, kidney disease, pharma, renal, type 2 diabetesm diabetes

Johnson & Johnson and research arm Janssen have taken the decision to terminate a Phase 3 trial evaluating the efficacy …

News

AbbVie and Janssen announce failure of cancer drug Imbruvica in Phase 3 trial

July 12, 2018
Research and Development AbbVie, Cancer, FDA, Janssen, approval

AbbVie and Janssen have announced that Imbruvica (ibrutinib) failed to achieve the primary endpoint in a late-stage study assessing its …

News

Janssen’s Tremfya gets go-ahead from NICE in plaque psoriasis

May 11, 2018
Medical Communications, Sales and Marketing Janssen, NICE, Tremfya, UK, pharma, psoriasis

NICE, the UK’s drug watchdog for the NHS, has decided that Janssen’s Tremfya (guselkumab) should be used routinely through the …

News

Genmab and Janssen’s Darzalex combo scores FDA approval in multiple myeloma

May 8, 2018
Manufacturing and Production, Sales and Marketing FDA, Genmab, Janssen, US, darzalex, multiple myeloma, pharma

Genmab and Janssen have revealed that their combination of Darzalex (daratumumab) with bortezomib (Velcade), melphalan, and prednisone (VMP) has received …

News
kris-sterkens-23052017-hr-1

Working Life: Kris Sterkens, Company Group Chairman, Janssen EMEA

April 12, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing J&J, JJ, Janssen, Johnson & Johnson, Kris Sterkens, pharma

Pharmafile.com sat down with Kris Sterkens, Company Group Chairman of Janssen’s EMEA operations to discuss nearly three decades at the …

Feature
pharmafocus_april_2018_cover

The April 2018 issue of Pharmafocus is now live!

March 27, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Janssen, Martin Shkreli, Right to try, atrial fibrillation, falsified medicines directive, oncology, opioids, pharma

As we finally pass into Spring after what still feels like a particularly stubborn Winter, we are pleased to announce …

News
janssen_latest_logo_on_sign

Janssen’s Tremfya shows long-term efficacy in moderate to severe plaque psoriasis

February 19, 2018
Research and Development, Sales and Marketing Janssen, Tremfyam guselkumab, pharma, plaque psoriasis, psoriasis

Janssen has unveiled new Phase 3 trial data for its IL-23 inhibitor Tremfya (guselkumab), demonstrating that the drug was able …

News

FDA expands J&J Zytiga combo’s indication to include castration-sensitive prostate cancer

February 9, 2018
Medical Communications, Sales and Marketing Cancer, FDA, J&J, JJ, Janssen, Johnson & Johnson, Zytiga, pharma

Johnson & Johnson has announced that Zytiga (abiraterone acetate) in combination with prednisone has been awarded FDA approval in the …

News

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023